BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'shares rise'. (Return)

Yahoo BusinessJul 14, 2020
Analyst Predicts Approval for Moderna's COVID-19 Vaccine
Shares of the vaccine maker Moderna (MRNA) are up by double digits in after-hours session Tuesday, thanks to a positive clinical update for its experimental coronavirus vaccine mRNA-1273. "Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study," said Tal Zaks, Chief Medical Officer of Moderna.Following Moderna's massive gains so far this year, 333% to be exact, is now the right time to recommend investors snap up shares? Jefferies analyst Michael Yee has an almost Schwarzenegger-ish answer to such a question: "We take a stand: If it works, stock will be going up."To this end, Yee initiated coverage on MRNA with a Buy rating. However, his $90 price target implies a modest 5% upside from current levels. (To watch Yee's track record, click here)Unsurprisingly, the bulk of Yee's bullish assessment is reserved for the company's COVID-19 vaccine candidate.Expanding on this blunt assessment, Yee said, "We believe the Street will be surprised to the upside if the COVID-19 vaccine works, gets approved by early 2021, and there are multi-billion dollars of purchase orders from USA and around the world. The Street is divided as to what will happen or if the vaccine will even work and is hugely divided on valuation. We believe the vaccine will get approved and could do $5B in orders over the next few years and the stock will head higher."Yee's confidence is

Yahoo BusinessJul 14, 2020
Vaxart: No Midnight Bells Ringing Yet for This Cinderella Biotech Story
It has been a breakout year for vaccine specialist Vaxart (VXRT). Entering 2020, the company had a market cap just below a puny $17 million. Since then, shares have exploded by an incredible 4748% as investors have piled in with the hope Vaxart can be the surprise provider of the coveted COVID-19 vaccine.However, Vaxart stock still has plenty left in the tank, according to B Riley FBR analyst Mayank Mamtani. The 5-star analyst believes that, based on the company's proprietary VAAST (vector-adjuvant-antigen standardized technology) vaccine platform, Vaxart's "one-of-its-kind oral solution," could set it apart from the competition.Mamtani added, "We believe clinical proof of concept from norovirus and influenza programs validates VAAST's targeted immune system activation approach with enteric-coated tablets designed to release a vaccine specifically in the small intestine. This activation of gut immunity provides protection at the inner linings of the GI and respiratory tracts and is a key differentiator versus other platform approaches, in our view."Apart from the convenience of an oral solution instead of the more commonly used injection, Vaxart's approach has logistical advantages, and its worldwide distribution would cause "only a minimal incremental burden to the global vaccine supply chain." Moreover, the unique approach could increase global vaccination rates because it is one well suited to developing counties whose less advanced healthcare systems are already under duress due to the
TRENDING TAGS
coronavirusvaccine Moderna trial cases Pandemic
COVID-19vaccine final trial testing Moderna
VaccineModerna coronavirus trial COVID-19 Results
StockToday Earnings market Moderna investors
pandemicCoronavirus during How amid Delta
ChinaHong Kong Trump sanctions signs
EarningsQ2 Call Transcript Season JPMorgan
Modernavaccine coronavirus trial Results Stock
StocksEarnings Season investors early making
TaxDay deadline time File due

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC